News
Today is Rare Disease Day and many companies, both pharma and rare disease organisations, have announced their support for this awareness initiative. Today marks the sixth international Rare Disease Day, led by EURORDIS, to raise awareness for patients with rare…
Bayer’s Stivarga has had its approval expanded through the FDA’s priority review program to treat rare disease patients with GIST. The US FDA approval of Bayer’s Stivarga has been expanded so as to treat rare disease patients with advanced…
UCB reports a 7% revenue growth for the full-year 2012, largely due to its core medicines in the areas of the central nervous system and immunology. UCB has announced that its core medicines were key to the company’s growth in 2012. Revenue increased by…
Phase 3 clinical trial data shows that Boehringer Ingelheim’s asthma drug significantly improved lung function over a 24-week period. Boehringer Ingelheim has announced positive phase 3 clinical trial data for its asthma drug, tiotropium Respimat. The…
Dynavax’s adult hepatitis B vaccine has been rejected for approval by the US FDA, who has requested additional data regarding the broad age indication of the vaccination. The US FDA has rejected Dynaxax Technologies’ Biologic License Application for its investigational adult…
Roche has vowed to increase access to its clinical trial data and has acknowledged the public’s interest in the missing tamiflu data. Swiss pharmaceutical company Roche has announced it is expanding access to its clinical trial data for third…
With Rare Disease Day tomorrow, its coordinator EURORDIS has honoured Sanofi’s Genzyme with the highly acclaimed Company Award for its rare disease accomplishments. The largest European rare disease patient organisation EURORDIS has awarded Sanofi’s subsidiary, Genzyme, with…
The US Food and Drug Administration has approved Genentech’s new breast cancer therapy through its priority review system. Roche’s Genentech has announced that the US FDA has approved its new breast cancer therapy…
Pfizer and CDRD Ventures Inc have announced a strategic collaboration to advance Canada’s promising health technologies towards commercialisation. The Centre for Drug Research and Development’s CDRD Ventures Inc (CVI) has announced a strategic collaboration with…
